More is better: Combination therapies for myelodysplastic syndromes | Aplastic Anemia and MDS International Foundation

More is better: Combination therapies for myelodysplastic syndromes

Journal Title: 
Best Pract Res Clin Haematol
Author(s): 
Ornstein MC, Mukherjee S, Sekeres MA
Primary Author: 
Ornstein MC
Original Publication Date: 
Sunday, March 1, 2015

The myelodysplastic syndromes (MDS) are a heterogenous collection of clonal hematopoietic malignancies that exist as a subgroup of the myeloid neoplasms as classified by the World Health Organization (WHO). They are characterized by ineffective hematopoiesis, subsequent cytopenias, transformation to acute myeloid leukemia (AML), and poor overall survival. There are currently three FDA-approved medications for MDS; lenalidomide, azacitidine, and decitabine. The role of these agents is to diminish the clinical impact of MDS and delay its progression to AML. However, despite known results with these monotherapies, recent clinical trials with a variety of combinations for MDS have demonstrated promising results. These trials include combinations of hypomethylating agents, histone deacetylase inhibitors, growth factors, and chemotherapy among others. In this paper we review the current literature on combination therapies in MDS, analyze on-going and concluded trials, and suggest future possibilities for combination strategies in MDS.

Bone Marrow Diseases: